Value through Innovation22 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


New Pradaxa® data to be presented at the ESC Congress 2014

- For Non-US/Non-UK/Non-Canadian Media

Boehringer Ingelheim Animal Health celebrates 20 years of PRRS control and innovation


First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting

- For Non-US/Non-UK/Non-Canadian Media

First half year 2014: Boehringer Ingelheim meets challenges


Boehringer Ingelheim receives two FDA approvals

- For Non-US/Non-UK media only

Pradaxa® (dabigatran etexilate) Video Statement

- For media outside UK, U.S. and Canada

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

- For media outside UK, U.S. and Canada

Boehringer Ingelheim Establishes a Research Alliance with the University of Toronto, the Toronto-based University Health Network and the Mount Sinai Hospital to investigate new therapeutic concepts in the field of ubiquitin signalling biology


Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA breakthrough therapy designation in IPF

- For non-US media only

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

- For media outside of the US/UK only

Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience

- For Non-US, Non-UK Media Only

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote

- For media outside of the U.S., the UK & Canada only

CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union

- For Non-U.S. and Non-U.K. Media

Boehringer Ingelheim Statement on Hepatitis C drug development

- For media outside of the US, the UK only

New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation

- For media outside of the U.S., the UK & Canada only

Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

- For Non-U.S. and Non-U.K. Media

New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia

- For media outside of the US/UK only

Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition

- For Non-US and Non-UK Media